Xia Ziyuan, Huang Meijin, Zhu Qiangqiang, Li Yinghua, Ma Qian, Wang Yang, Chen Xia, Li Jianzhong, Qiu Lei, Zhang Junping, Zheng Jiaoyang, Lu Bin
Department of Biochemical Pharmacy, School of Pharmacy, Second Military Medical University, Shanghai, China.
Department of Oncology, 920th Hospital of PLA Joint Logistics support Force, Yunnan, China.
J Cancer. 2019 Jan 29;10(4):864-873. doi: 10.7150/jca.27663. eCollection 2019.
Cadherin related family member 2 (CDHR2) belongs to the protocadherin family and is abundant in normal liver, kidney, and colon tissues, but weakly expressed in cancers arising from these tissues. In this study, we demonstrated that CDHR2 was highly expressed in para-cancer tissues of human hepatocellular carcinoma (HCC), but significantly downregulated or silenced in 85.7% (6/7) of HCC cell lines by both semi-quantitative PCR and western blot, and 79.1% (19/24) and 80.2% (89/111) of tumor tissues from patients with HCC by semi-quantitative PCR, and immunohistochemistry, respectively. Interestingly, CpG islands in the promoter of CDHR2 gene were hypermethylated in HCC cell lines and tissues compared with the para-cancer tissues by methylation-specific PCR analysis, leading to transcriptional repression and silencing of CDHR2 in HCC. In addition, CDHR2 overexpression by lentiviral vectors had suppressive effects on HCC cell growth and proliferation, as evidenced by prolonged cell doubling time and reduced colony-forming ability , as well as by decreased tumorigenicity Mechanistically, CDHR2 overexpression resulted in AKT dephosphorylation along with downregulation of cyclooxygenase-2 (COX2), a downstream target of AKT. This effect was reversed by myristoylated AKT, a constitutively active form of AKT, suggesting an involvement of CDHR2-AKT-COX2 axis in the suppression of HCC growth. Taken together, our study identified CDHR2 as a novel tumor suppressor in HCC and provided a new therapeutic target for HCC.
钙黏蛋白相关家族成员2(CDHR2)属于原钙黏蛋白家族,在正常肝脏、肾脏和结肠组织中含量丰富,但在这些组织发生的癌症中表达较弱。在本研究中,我们证明CDHR2在人肝细胞癌(HCC)的癌旁组织中高表达,但通过半定量PCR和蛋白质印迹法检测发现,在85.7%(6/7)的HCC细胞系中显著下调或沉默;通过半定量PCR和免疫组织化学检测分别发现,在79.1%(19/24)的HCC患者肿瘤组织和80.2%(89/111)的HCC患者肿瘤组织中显著下调或沉默。有趣的是,通过甲基化特异性PCR分析发现,与癌旁组织相比,HCC细胞系和组织中CDHR2基因启动子中的CpG岛发生了高甲基化,导致HCC中CDHR2转录抑制和沉默。此外,慢病毒载体介导的CDHR2过表达对HCC细胞生长和增殖具有抑制作用,细胞倍增时间延长、集落形成能力降低以及致瘤性降低均证明了这一点。机制上,CDHR2过表达导致AKT去磷酸化,同时环氧合酶-2(COX2)(AKT的下游靶点)表达下调。组成型活性形式的AKT——肉豆蔻酰化AKT可逆转这种作用,提示CDHR2-AKT-COX2轴参与了对HCC生长的抑制。综上所述,我们的研究确定CDHR2是HCC中的一种新型肿瘤抑制因子,并为HCC提供了一个新的治疗靶点。